Paper
0
Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial
Authors
Mark Parsons,Vignan Yogendrakumar
Leonid Churilov,Carlos García-Esperón,Bruce Campbell,Mary Russell,Gagan Sharma,Chushuang Chen,Sunil Munshi,Felix Ng,Akshay Deepak,Philip Choi,Timothy Kleinig,Dennis Cordato,Teddy Wu,John Fink,Thanh Phan,Carlos Molina,Chon‐Haw Tsai,Jiunn‐Tay Lee,Jiann‐Shing Jeng,Daniel Strbian,Juan Arenillas,Brian Buck,Michael Devlin,Kennedy Lees,Arman Sabet,Tissa Wijeratne,Andrew Bivard,Rohan Grimley,Smriti Agarwal,Geoffrey Donnan,Stephen Davis,Ferdinand Miteff,Neil Spratt,Christopher Levi
+34 authors
,Леонид ЧуриловJournal
Published
Jun 13, 2024
Show more
Save
Tip0
TipSave
Abstract
Intravenous tenecteplase increases reperfusion in patients with salvageable brain tissue on perfusion imaging and might have advantages over alteplase as a thrombolytic for ischaemic stroke. We aimed to assess the non-inferiority of tenecteplase versus alteplase on clinical outcomes in patients selected by use of perfusion imaging.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.